Anaphylaxis Market Report 2032: Epidemiology Data, Treatment Market, Therapies, Companies and Competitive Analysis by DelveInsight | Amneal Pharmaceuticals, Bioprojet, Mylan N.V, Adamis Pharmaceutical

April 27 22:33 2023
Anaphylaxis Market Report 2032: Epidemiology Data, Treatment Market, Therapies, Companies and Competitive Analysis by DelveInsight | Amneal Pharmaceuticals, Bioprojet, Mylan N.V, Adamis Pharmaceutical
Anaphylaxis Market

(New York, USA) DelveInsight’s “Anaphylaxis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Anaphylaxis, historical and forecasted epidemiology as well as the Anaphylaxis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Anaphylaxis Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Anaphylaxis market. A detailed review of the historical and forecasted Anaphylaxis market is included in the report, covering drug outreach in the 7MM.


Request for a Free Sample Report @ Anaphylaxis Market Forecast


Some of the key highlights of the Anaphylaxis Market Report

  • According to DelveInsight, the Anaphylaxis market is expected to grow at a decent CAGR by 2032.
  • Leading Anaphylaxis companies working in the treatment market are Amneal Pharmaceuticals Inc., Bioprojet, Mylan N.V., Adamis Pharmaceutical Corporation, Abbott, Pfizer Inc., Glaxosmithkline Plc., Merck, Teva Pharmaceutical Industries Ltd., ALK-ABELLÃ and others.
  • Promising Anaphylaxis therapies are AbbieSense technology, AQST-109, AQST-108, Symjepi, EpiPen and EpiPen Jr, and others.
  • A study titled “The Epidemiology of Anaphylaxis”, wherein the lifetime prevalence of anaphylaxis was estimated at 0.05–2% in the USA and approximately 3% in Europe. The study also mentioned that in UK, of patients presenting to paramedics and first aides estimated 0.2% of emergency cases due to anaphylaxis.
  • Biphasic anaphylaxis is a recurrence of anaphylaxis after appropriate treatment. It happens with no additional exposure to the allergen and strikes after the patient has survived the initial attack.
  • Anaphylaxis develops rapidly, usually reaching peak severity within 5 to 30 minutes, and may, rarely, last for several days.
  • Approximately 1 in 5 admissions to hospitals in England due to allergies were for an anaphylactic reaction (4070 out of 20,318). This was an increase of 9.9% on the same period in the previous year. The NICE CG134 guideline reported an available UK estimate that about 1 in 1,333 of the population of England had experienced anaphylaxis at some point in their lives. However, a systematic review published in 2013 estimated that 1 in 300 people in Europe were affected by anaphylaxis at some point in their lives


Learn more about Anaphylaxis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @


Anaphylaxis Overview:

Anaphylaxis is an acute, potentially life-threatening, generalized, or systemic allergic reaction that is mediated by the degranulation of mast cells and basophils. The condition usually develops suddenly and gets worse very quickly. Anaphylaxis symptoms include feeling lightheaded or faint, breathing difficulties – such as fast, shallow breathing, wheezing, fast heartbeat, clammy skin, confusion and anxiety, collapsing or losing consciousness. There may also be other allergy symptoms, including an itchy, raised rash (hives), feeling or being sick, swelling (angioedema) or stomach pain.


Anaphylaxis Epidemiology Insights

The lifetime prevalence of anaphylaxis has been estimated at 1.6% to 5.1%. Medications and stinging insects are the leading triggers in adults, with foods and stinging insects the most frequently implicated triggers in children and adolescents. Food allergy impacts 8% to 11% of children and adults in the United States, while adverse drug reactions (ADRs) affect up to 10% of the population (and 20% of hospitalized patients), with hypersensitivity reactions (HSRs) accounting for 10% of all ADRs.

Anaphylaxis Epidemiology Segmentation in the 7MM (2019-2032)

  • Anaphylaxis Prevalent Population
  • Anaphylaxis Diagnosed and Treatable Cases
  • Anaphylaxis Trigger-specific Population


Explore more about Anaphylaxis Epidemiology @


Anaphylaxis Market Insights

Anaphylaxis is variable and unpredictable. It may be mild and resolve spontaneously due to endogenous production of compensatory mediators or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death. The treatment for anaphylaxis majorly includes the use of epinephrine to prevent the possible progression to life-threatening manifestations. When the patient is admitted at the hospital, they might receive glucocorticoid and antihistamines intravenously. These medications help to reduce inflammation in the air passages, improving your ability to breathe. They may also be given beta-agonists such as albuterol to make breathing easier and may also receive supplemental oxygen to help the body get the oxygen it needs.


Get a sample copy of the Anaphylaxis Market report here @


Anaphylaxis Therapeutics Assessment

Major key companies are working proactively in the Anaphylaxis Therapeutics market to develop novel therapies which will drive the Anaphylaxis treatment markets in the upcoming years is Amneal Pharmaceuticals Inc., Bioprojet, Mylan N.V., Adamis Pharmaceutical Corporation, Abbott, Pfizer Inc., GlaxoSmithKline Plc., Merck, Teva Pharmaceutical Industries Ltd., ALK-ABELLÃ and others.


Learn more about the emerging Anaphylaxis therapies & key companies @


Anaphylaxis Report Key Insights

1. Anaphylaxis Patient Population

2. Anaphylaxis Market Size and Trends

3. Key Cross Competition in the Anaphylaxis Market

4. Anaphylaxis Market Dynamics (Key Drivers and Barriers)

5. Anaphylaxis Market Opportunities

6. Anaphylaxis Therapeutic Approaches

7. Anaphylaxis Pipeline Analysis

8. Anaphylaxis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Anaphylaxis Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Anaphylaxis Competitive Intelligence Analysis

4. Anaphylaxis Market Overview at a Glance

5. Anaphylaxis Disease Background and Overview

6. Anaphylaxis Patient Journey

7. Anaphylaxis Epidemiology and Patient Population

8. Anaphylaxis Treatment Algorithm, Current Treatment, and Medical Practices

9. Anaphylaxis Unmet Needs

10. Key Endpoints of Anaphylaxis Treatment

11. Anaphylaxis Marketed Products

12. Anaphylaxis Emerging Therapies

13. Anaphylaxis Seven Major Market Analysis

14. Attribute Analysis

15. Anaphylaxis Market Outlook (7 major markets)

16. Anaphylaxis Access and Reimbursement Overview

17. KOL Views on the Anaphylaxis Market

18. Anaphylaxis Market Drivers

19. Anaphylaxis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States